1. General Specification (hauv Tshuag)
(1) API (Ntshiab hmoov)
(2) Tablet
(3) Capsule
(4) Txhaj tshuaj
(5) Ua kua dej
2.Customization:
Peb yuav sib tham tus kheej, OEM / ODM, Tsis muaj hom, rau kev tshawb nrhiav kev ruaj ntseg nkaus xwb.
Internal Code: BM-3-094
GLP-1 CAS Nr .: 87805-34-3
Lub khw tseem ceeb: Tebchaws Asmeskas, Australia, Brazil, Nyiv, Lub Tebchaws Yelemees, Indonesia, UK, New Zealand, Canada thiab lwm yam.
Chaw tsim tshuaj paus: BLOOM TECH Xi'an Hoobkas
Kev tshuaj xyuas: HPLC, LC-MS, HNMR
Kev them nyiaj yug Technology: R&D Dept.-4
Peb muab GLP-1 Txhaj, thov xa mus rau lub vev xaib hauv qab no kom paub meej cov lus qhia tshwj xeeb thiab cov ntaub ntawv khoom.
Khoom siv:https://www.bloomtechz.com/oem-odm/injection/glp-1-injections.html
Geli Pharmaceutical's GLP-1 cov tshuaj tshiab ASC30 tau ua tiav theem II kev kho mob hauv Tebchaws Meskas
Thaum Lub Peb Hlis 10, 2026, Geli Pharmaceutical Co., Ltd. (Hong Kong Tshuag Txauv code: 1672, abbreviated li "Geli") tshaj tawm tias nws cov molecule GLP-1 receptor (GLP-1 R) agonist ASC30 subcutaneous depot formulation rau kev kho mob rog rog hauv Tebchaws Meskas 2 lub limtiam kev kawm hauv internet, (NCT06679959), ua tiav cov txiaj ntsig zoo saum toj kawg nkaus. Tag nrho ntawm 65 qhov kev kawm tau cuv npe hauv peb pawg, thiab ob qho qauv (A1 thiab A2) tau tswj hwm. Tag nrho cov kev kawm yog cov rog rog lossis rog rog nrog tsawg kawg ib qho hnyav txog qhov teeb meem, Txoj kev tshawb fawb Chuan tau ua tiav nws cov ntsiab lus kawg, nrog cov neeg mob tau txais 3 koob tshuaj (ib hlis ib zaug) ntawm ASC30 subcutaneous reservoir formulation A1 qhia qhov tseem ceeb (piv rau cov placebo, p.<0.05) and clinically significant mean weight gain of 6.3% (after placebo adjustment) at week 12.
Tsis tas li ntawd, ASC30 subcutaneous cia formulation A1 tau pom qhov tseem ceeb (piv rau cov placebo, p.<0.05) and clinically significant average weight loss of 7.5% (after placebo correction) at 16 weeks of pen administration once a month for a total of 3 doses.
ASC30 yog ib qho me me molecule GLP-1R agonist tam sim no tab tom tshawb fawb soj ntsuam, nrog cov khoom tshwj xeeb thiab sib txawv uas ua rau nws ua tau rau tib lub me me molecule siv rau ob lub qhov ncauj ntsiav tshuaj thiab txhaj tshuaj subcutaneous. ASC30 yog lub chaw tshuaj lom neeg tshiab (NCE) nrog Asmeskas thiab thoob ntiaj teb kev tiv thaiv patent, nrog rau lub sijhawm tiv thaiv patent mus txog 2044 (tsis suav nrog cov peev txheej patent txuas ntxiv).
Lilly nqis peev $ 3 nphom txhawm rau nce nws cov khoom siv hauv Suav teb
Thaum Lub Peb Hlis 11, 2026, Eli Lilly tshaj tawm cov phiaj xwm los nqis peev tag nrho ntawm $ 3 nphom hauv kaum xyoo tom ntej kom nthuav dav nws cov khoom siv muaj peev xwm hauv Suav teb, tsim kom muaj kev tsim khoom hauv zos thiab cov khoom siv rau kev npaj ntawm qhov ncauj, thiab tsom mus rau kev nthuav dav cov peev txheej ntawm thawj lub qhov ncauj me me molecule GLP-1 receptor agonist, orforglipron. Qhov kev nqis peev no yog lwm qhov kev ntsuas tseem ceeb rau Lilly kom tob zuj zus nws cov qoob loo hauv Suav teb thiab txhawb kev txhim kho kev lag luam kho mob hauv zos. Lilly Tuam Tshoj tau xa daim ntawv thov kev lag luam ntawm orforqlipron rau kev kho mob ntshav qab zib hom 2 thiab kev rog rog rau Lub Xeev Kev Tswj Xyuas Tshuaj thaum kawg ntawm 2025. Raws li ib feem tseem ceeb ntawm qhov kev nqis peev no, Lilly npaj yuav ua haujlwm nrog ntau tus neeg koom tes hauv zos los npaj thiab teeb tsa yav tom ntej cov raj xa dej loj loj, suav nrog orforglipron. Lilly tshaj tawm txoj kev koom tes nrog Kanglong Chemical, nrog rau kev npaj peev ntawm 200 lab US las thiab kev txhawb nqa rau nws lub peev xwm thev naus laus zis. Cov nplai yuav maj mam nthuav mus rau yav tom ntej nyob ntawm kev txhim kho.
Qhov kev nqis peev no yuav tau txais kev sib koom ua ke ntawm kev nthuav dav sab hauv thiab kev koom tes sab nraud: ntawm ib sab, vam khom rau cov txuj ci thiab txuj ci zoo ntawm Lilly Suzhou Hoobkas, peb yuav ntxiv dag zog rau kev sib koom tes tsim khoom; Ntawm qhov tod tes, peb koom tes nrog ntau tus neeg tsim khoom hauv zos los tso cov peev txheej ntau lawm. Qhov kev nqis peev no yuav tsum muaj peev xwm nce ntxiv, thaum ua tau raws li cov kev xav tau ntawm cov neeg mob hauv Suav teb thiab tsim kom muaj txiaj ntsig rau kev lag luam hauv zos, kev loj hlob ntawm kev lag luam, thiab kev ua haujlwm. Orforge lipon yog ib qho me me molecule (tsis yog peptide) glucagon zoo li peptide-1 receptor agonist (GLP-1 RA) uas tam sim no nyob rau hauv txoj kev loj hlob thiab tswj qhov ncauj ib hnub ib zaug. Cov tshuaj no tuaj yeem noj txhua lub sijhawm ntawm hnub tsis muaj kev txwv rau kev noj zaub mov thiab dej kom tsawg. Cov tshuaj no tau tshawb pom los ntawm Chugai Pharmaceutical Co., Ltd. thiab tau tso cai rau kev txhim kho los ntawm Eli Lilly xyoo 2018.